Answers are grounded in this paper and cite their sources.
Objective: To determine if there was a difference in safety, effectiveness, or antimicrobial utilization before and after this change in antimicrobial susceptibility reporting. Design: Pre-intervention, post-intervention quasi-experimental study. Setting: Two affiliated academic medical centers in St. Louis, Missouri; a tertiary-care adult hospital and a pediatric hospital. Patients: Inpatients at Barnes-Jewish and St. Louis Children’s Hospitals with first-positive Serratia marcescens culture and ≥48 hours of definitive therapy. Exclusions included concomitant resistant gram-negative infections, ocular or corneal cultures, and death prior to susceptibility results. Methods: Prior to October 2023, S. marcescens isolates were standardly reported as resistant to ceftriaxone, ceftazidime, and piperacillin/tazobactam regardless of susceptibility testing results; the intervention was to report susceptibility results as tested. The primary outcome was AmpC-stable beta-lactam inpatient days of therapy (DOT). Results: A total of 166 patients were included; 78 pre-intervention and 88 post-intervention. The median (interquartile range) total DOT for AmpC-stable beta-lactams was 8 (4.8–15.0) in the pre-intervention vs 5 (3.0–8.3) in the post-intervention group ( P < .001). In patients treated with ≥72 hours of AmpC-labile beta-lactams with repeat cultures, there was no resistance emergence in subsequent isolates (0/26). No statistically significant differences in hospital mortality, inadequate response, or retreatment were observed. Conclusions: A change in susceptibility reporting for S. marcescens was associated with a decrease in AmpC-stable beta-lactam use and no statistically significant changes in clinical or microbiological outcomes.
No takes yet. Share an insight, caveat, or question.
Bishop et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: